Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
05/18/2022 - 08:00 AM
BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Executive Officer, Eric Richman, will present and host one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23-25 in Miami, Florida. Please see additional details below:
H.C. Wainwright Global Investment Conference Date: May 24, 2022 Time: 1:30PM ET Format: Corporate Presentation Webcast: Registration link
A live webcast of the presentation can be accessed through the Events section of the Company’s website at https://www.gaintherapeutics.com/investors-media/overview.html . An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com .
Investor & Media Contact:
Noor Pahlavi Argot Partners (212) 600-1902Gain@argotpartners.com
GANX Rankings
#2931 Ranked by Stock Gains
GANX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About GANX
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.